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1. Introduction 
Helicobacter pylori (H. pylori) infection is a main risk factor for the development of gastric 
cancer (Correa et al., 1990; Sipponen & Hyvarinen, 1993; International Agency for Research 
on Cancer [IARC], 1994; Graham, 2000; Uemura et al., 2001). It has been postulated that H. 
pylori infection causes chronic gastritis, gastric atrophy, usually with gastric intestinal 
mataplasia (GIM) and dysplasia, and gastric cancer. The stepwise fashion of this infection, 
which usually continues over decades, has been defined as a sequence of histological events 
that confer an increasing risk of malignant transformation as described in Correa’s 
hypothesis (Correa & Shiao, 1994). Although it is fairly well accepted that H. pylori infection 
plays a significant role in causing gastric cancer, the exact mechanisms involved in the 
pathogenesis remain obscure. In general, GIM is believed to be a preneoplastic lesion of the 
stomach (Correa, 1995), which increases the risk of gastric adenocarcinoma, especially 
intestinal type (Correa & Shiao, 1994; Correa, 1988). It remains unclear, however, as to 
whether or not GIM is a precancerous lesion or a marker for an increased risk of malignancy 
(Filipe et al., 1994; Miehlke et al., 1998).   
Although there are many reports regarding the histological changes including metaplasia 
and dysplasia following eradication of H. pylori, the results have been conflicting (Table 1).  
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Study Materials Follow-up period 
Improvement 
  Genta RM, et al.  
  Uemura N, et al.  
  Nardone G, et al.  
    Sung JJ, et al.  
    Ohkusa T, et al.  
    Kokkola A, et al.  
    Correa P, et al.  
    Ley C, et al.  
    Mera R, et al.  
    You WC, et al.  
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    Witteman EM, et al.  
    Forbes GM, et al. 
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    Hibi K et al. 
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    El-Omar EM, et al. 
    Kim N, et al. 
 
    Kuipers EJ, et al. 
    Tanaka A, et al. 
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Duodenal ulcer (n=9) 
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Duodenal ulcer (n=63) 
Cancer patients’ relatives (n=40) 
Gastric ulcer (n=41) 
Duodenal ulcer (n=72) 
Reflux esophagitis (n=231) 
Atrophic gastritis (n=39) 



























Table 1. Summary of studies on changes of GIM scores after successful H. pylori eradication 
Some reported that the histologic grade of GIM had improved after eradication (Genta et al., 
1993; Uemura et al., 1997; Nardone et al., 1999; Sung et al., 2000; Ohkusa et al., 2001; Kokkola 
et al., 2002; Correa et al., 2000; Ley et al., 2004; Mera et al., 2005; You et al., 2006) but the 
others did not find any change (Witteman et al., 1995; Forbes et al., 1996; van der Hulst et al., 
1997; Hibi et al., 1997; Satoh et al., 1998; Tucci A et al., 1998; Tepes et al., 1999; El-Omar et al., 
2000 ; Kim et al., 2000 ; Kuipers et al., 2004 ; Tanaka et al., 2006). Some of the reasons for 
these discrepancies may be ethnic variations, completeness of eradication of the disease and 
the stage of the disease when treatment is initiated and short follow-up (most studies up to 1 
year) (Kokkola et al., 2002; Forbes et al., 1996; Tucci A et al., 1998; Tepes et al., 1999; Kim et 
al., 2000; Tanaka et al., 2006). Uemura et al (Uemura et al, 1997) studied the changes of GIM 
after treatment of H. pylori in the patients with intramucosal gastric cancer who underwent 
endoscopic mucosal resection (EMR). In this study, they showed that GIM score regressed at 
6 months after H. pylori eradication. To our knowledge, however, there are no studies about 
the long-term effects after H. pylori eradication on the difference of histologic changes of 
GIM between the patients with and without gastric neoplasms. 
We developed a monoclonal antibody (mAb), Das-1 (formerly known as 7E12H12, IgM 
isotype), that specifically reacts with colonic epithelium (Das et al. 1987). Using both 
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immunoperoxidase and immunofluorescence assays, we and others have demonstrated that 
the antibody specifically reacts with colonic epithelium (both goblet and non-goblet 
absorptive cells), but not with enterocytes (including goblet cells) from jejunum or ileum 
and normal epithelium from the stomach and esophagus (Das et al. 1987; Halstensen et al., 
1993). However, mAb Das-1 reacts sensitively (95%) and specifically (100%) to Barrett’s 
epithelium (BE), a pre-neoplastic condition of the esophagus, and adenocarcinoma of the 
esophagus (Das et al. 1994; Griffel et al., 2000). These data support that BE is a “colonic” or 
“incomplete” type of intestinal metaplasia (Das et al. 1994). Although normal small 
intestinal epithelium does not react with mAb Das-1, small intestinal adenoma and 
adenocarcinoma strongly react with the antibody, suggesting a phenotypic change in the 
pre-cancerous state and in carcinoma (Onuma et al., 2001). We also reported that GIM of 
colonic phenotype, such as type II or type III (incomplete type) detected by the mucin 
histochemistry (Filipe & Jass, 1986) and detected by mAb Das-1, is strongly associated with 
gastric cancer (Mirza et al., 2002). Ninety-three percent of GIM as well as gastric cancer from 
the same patients at a different area reacted with mAb Das-1, whereas GIM from patients 
without gastric cancer reacted less frequently (35%) with the antibody (p<0.0001) (Mirza et 
al., 2002). 
More recently, during screening a complimentary DNA library prepared from a human 
colon cancer cell line, T84, we isolated and cloned a novel human tropomyosin (hTM) 
isoform, termed TC22 (Lin et al. 2002). The amino acid sequence analysis of TC22 
demonstrated that it is identical to normal colon epithelial tropomyosin isoform 5 (hTM5) 
except the C-terminal peptide aminoacids 222-247 coding exon 9. Using this C terminal 
peptide, we developed a mAb, termed TC22-4, which is specific to TC22 (Lin et al. 2002). 
The expression of TC22, identified by the TC22-4 mAb, progressively increased in benign 
adenomatous polyp of colon (35%) and polyps with mild (57%) and severe dysplasia (100%) 
and in colon cancer (100%) (Lin et al., 2002). hTMs are microfilament-associated proteins 
present in all eukaryotic cells with organ-specific isoforms and distinct functions (Lees-
Miller & Helfman, 1991; Pittenger & Helfman, 1992; Lin et al, 1997), and at least 8 isoforms 
of hTM are detected in human (Lin et al, 1997; Novy et al. 1993). hTM isoform 5 (hTM5) is 
the predominant isoform in normal colon epithelium and it acts as an autoantigen in 
ulcerative colitis (UC) (Das et al., 1993; Geng et al. 1998). We and others have shown that 
patients with UC demonstrate both humoral and cellular immune responses against hTM, 
particularly against isoform 5 (hTM5) (Das et al., 1993; Geng et al. 1998; Onuma et al., 2000; 
Biancone et al., 1995 ; Sakamaki et al., 2000 ; Taniguchi et al., 2001).  
A K-ras mutation occurs relatively early in human carcinogenesis (Vogelstein et al., 1988), 
and it is detected in various types of human malignancies (Soh et al., 1993; Cooper 1995). 
Mutations of K-ras gene are found in ~10% of intestinal-type gastric cancer but they are 
rarely detected in the diffuse type (Tahara, 1993; Arber et al., 2000; Hiyama et al., 2002). 
Furthermore, a K-ras mutation has been detected in preneoplastic lesions, such as mucous 
cell hyperplasia of the pancreas, which current term is pancreatic intraepithelial neoplasia, 
grade 1, suffering from chronic inflammation and regenerative or dysplastic epithelia of 
ulcerative colitis (Yanagisawa et al., 1993; Chaubert et al. 1994). However, there have been 
only a few reports of this oncogene in H. pylori-associated chronic gastritis and GIM either 
with or without gastric cancer (Hiyama et al., 2002; Gong et al., 1999). Moreover, changes in 
K-ras mutations in GIM after H. pylori eradication have not yet been investigated.   
In addition to genetic alterations, one of the pathways by which H. pylori is linked to gastric 
carcinogenesis may be related to the disruption in the balance between gastric epithelial cell 
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proliferation and apoptosis as some investigators have reported (Moss et al., 1996; Wagner 
et al. 1997; Jones et al., 1997; Hoshi et al., 1999; Leung et al. 2001). However, such previous 
studies on the cell kinetics before and after H. pylori eradication have yielded conflicting 
results. 
Epidemiological studies indicate that Asian countries have a high prevalence of H. pylori 
infection, with a correspondingly high incidence of gastric cancer. The annual incidence rate 
of gastric cancer per 100,000 population in various Asian countries, as reported by Parkin et 
al (Parkin et al., 1997), is very high in the northern parts of Asia, especially in Japan. In this 
paragraph, we illustrated around our previous studies (Watari et al., 2007; Watari et al., 
2008) in the Japanese population, (i) if the eradication of H. pylori affects subsequent (over 
the course of up to 4 years) histological grade of GIM, (ii) if mAb Das-1 reactivity that 
identifies colonic phenotype of GIM associated with gastric carcinogenesis changes after 
eradication of H. pylori, and (iii) to assess the expression of the novel tropomyosin isoform 
TC22 in GIM before and after H. pylori treatment. p53 expression was also examined, in 
parallel. Additionally, we investigated (iv) if H. pylori eradication affects K-ras mutations 
and cell kinetics including cell proliferation and apoptosis in GIM.  
2. Patients and methods  
2.1 Study 1 
Gastric biopsy samples (during 288 endoscopic procedures) from 96 H. pylori-positive 
Japanese patients were obtained prior to introduction of therapy, and, subsequently, over a 
follow-up period of up to 4 years. In all patients, biopsy specimens were taken to assess H. 
pylori infection, two from the greater curvature of the antrum and two from the greater 
curvature of the corpus of the stomach. H. pylori status was analyzed in each patient by two 
methods: Wartin-Starry staining and H. pylori culture. A patient was regarded as positive for 
H. pylori if at least one is positive, and the patient received anti-H. pylori therapy. All of the 
patients underwent upper endoscopy again after 2 to 3 months post-therapy to ensure 
successful eradication of H. pylori, and then were followed-up with yearly endoscopy, up to 
4 years (mean 2.6 yrs, range; 1 to 4). At each endoscopy, successful eradication was 
documented by the above methods. None of the patients showed positive for H. pylori 
during the follow-up period.  
2.1.1 Histology and patient classification 
GIM was defined as replacement of the gastric epithelium by intestinal type epithelium, and 
was composed of two types; the presence of absorptive enterocytes with brush border along 
with goblet cells, or columnar cells with foamy cytoplasm, lacking brush border (Filipe et al., 
1994).     
In this study, the patients with chronic gastritis with gastric ulcers or gastroduodenal ulcers 
were included. Almost half of the patients (53.9%) had gastric ulcers and the remainder had 
both gastric as well as duodenal ulcers (Take et al. 2005). The patients with duodenal ulcer 
only were excluded because most duodenal ulcers were categorized as antral predominat 
gastritis (Uemura et al., 2001) or non-atrophic gastritis (Mera et al. 2005), which has a low 
risk for gastric cancer and difference from gastric and gastroduodenal ulcers in 
pathophysiology (Uemura et al., 2001; Take et al. 2005).  
The 96 H. pylori-positive patients were divided into 3 groups on the basis of history and 
initial histology by a single experienced pathologist (P.S.A.). Group CG (n=36) had 
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histologically chronic gastritis, but no GIM. This group was considered to correspond to 
non-metaplastic multifocal atrophic gastritis according to the global diagnosis by Mera et al 
(Mera et al. 2005). Thirty of the 36 patients had peptic ulcers, comprising 34 gastric ulcers 
and 2 gastroduodenal ulcers, and 6 patients had chronic gastritis without ulcer. Group IM 
consisted of patients with chronic gastritis with GIM (n=33). Twenty-six patients had gastric 
ulcers and 7 patients had gastroduedenal ulcers. Group DYS consisted of patients with 
dysplasia (n=27). This comprised low-grade dysplasia (n=13), high grade-dysplasia (n=13), 
and cancer with microinvasion to the submucosa (n=1). All patients in Group DYS 
underwent EMR for dysplasia, and then received treatment for H. pylori.   
Serial sections (4 µm) were made and consecutive sections were used for histologic 
examination by H&E staining, mucin stainings by alcian blue and high iron diamine, pH2.5 
(AB/HID), and for immunohistochemistry, as described below. All slides were sent from 
Japan to NJ, USA, and evaluated and scored for GIM according to the updated Sydney 
system (Dixon et al., 1996; Rugge et al., 2000) by a single pathologist (P.S.A.) in NJ, who was 
unaware of the patient groups and treatment status. Scores were given numerically as 
follows: 0 for absence, and 1, 2, 3 for mild, moderate, or severe GIM. The GIM score was 
assessed in the samples obtained from the antrum, including patients with dysplasia at a 
different site of the stomach (Group DYS). 
2.1.2 Alcian blue (pH2.5)/High iron diamine (AB/HID) staining 
Serial sections were stained with AB/HID to identify neutral mucins, sialomucins, and 
sulphomucins using the standard method (Filipe et al., 1994). Briefly, slides were immersed 
in HID solution for 24 hours at room temperature. Slides were rinsed with distilled water, 
and then stained with 1% Alcian blue (pH 2.5) for 30 minutes. Three phenotypes of GIM 
were classified as described by Filipe and Jass (Filipe & Jass, 1986) namely type I (complete 
or small intestinal type), types II & III (incomplete or colonic type). When more than one 
type of GIM coexisted in a given sample, the case was classified according to the dominant 
type present in the section. 
2.1.3 Immnoperoxidase assays with mAb Das-1, TC22-4, and anti-p53 
Serial sections were stained with mAb Das-1 (mouse IgM mAb highly specific against 
Barrett’s epithelium), TC22-4 (mouse IgG1 mAb against a novel tropomyosin isoform, TC22, 
specific for colon cancer) and anti-p53 monoclonal antibody, DO7 (mouse IgG 2b, Dako, 
Carpenteria, CA) using sensitive immnoperoxidase assays as described previously (Das et 
al., 1994; Mirza et al., 2003; Lin et al., 2002). Briefly, after deparaffinization and rehydration, 
free aldehydes were reduced with 0.05% sodium borohydride for 20 min at 4˚C. The tissue 
sections were treated with the antigen-retrieval technique for TC22 and p53 staining. They 
were then sequentially incubated with mAb Das-1, mAb TC22-4 and DO7 for 45 min at 
room temperature (for DO7), overnight at 4˚C (for mAb Das-1), and 5 hr at 4˚C (for mAb 
TC22-4), followed by biotinylated rabbit antimouse IgM or IgG (Dako), 3% hydrogen 
peroxide, and streptoavidin peroxidase (Dako). Subsequently, the slides were treated with 
diaminobenzidine-H2O2 solution for 20 min at room temperature. Each experiment included 
positive controls for mAb Das-1, normal colon section, and colon cancer tissue sections as 
positive controls for mAb TC22-4 and anti-p53 immunostainings. As negative controls, 
jejunum (for mAb Das-1) and normal colon (for TC22-4 and p53) were used. 
www.intechopen.com
 
Gastritis and Gastric Cancer – New Insights in Gastroprotection, Diagnosis and Treatments 
 
222 
2.2 Study 2 
We enrolled 64 patients with successful H. pylori treatment who had atrophic gastritis (n=39) 
and intestinal-type mucosal gastric cancer after EMR (n=25). Following successful 
eradication, all patients were followed up by endoscopy for 1 year. All these patients 
histologically showed GIM in gastric biopsy samples both before and after H. pylori 
eradication. In order to improve the accuracy regarding the genetic alterations, the number 
of samples was increased. Twenty-eight intestinal-type early gastric cancer cases that had 
undergone a surgical resection were randomly selected from the histopathology files of 
Asahikawa Medical University Hospital during the same period and thus were added to 
this study.  
Finally, the patients in this study included, Group IM (n=39): chronic gastritis cases with 
GIM, and Group DYS (n=53): intestinal-type early gastric cancer, further divided into Group 
DYS-1 (n=25): EMR cases diagnosed as mucosal cancer and Group DYS-2 (n=28): surgical 
resection cases, consisting of 10 mucosal cancers and 18 submucosal invasive cancers. All 
patients in Group DYS-1 underwent EMR for their mucosal cancer lesions, and thereafter 
received treatment for H. pylori. 
2.2.1 DNA preparation and detection of K-ras mutations  
Four tissue sections, each measuring 10 µm in thickness, were serially cut from paraffin 
embedded tissue blocks. DNA was extracted from only GIM (Fig. 1). In this procedure of 
DNA extraction, the tissue specimens were precisely microdissected under microscopic 
visualization, using a PixCell laser capture microdissection system (Arcturus Engineering, 
Mountain View, CA) to avoid any DNA contamination of inflammatory or stromal cell 
nuclei. DNA was then extracted from the microdissected tissue specimen by proteinase K 
treatment, followed by phenol-chloroform extraction.    
 
 
Fig. 1. Metaplastic glands were isolated by a laser capture microdissection. (A) H&E stained 
section, (B) The same section, after the removal of metaplastic glands. 
The detection of point mutations in codon 12 of the K-ras gene was performed by enriched 
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) as 
previously described with minor modifications (Levi et al., 1991; Sanger et al., 1997). The 
DNA from the K-ras sequence of exon 1 was amplified by a first PCR using the mismatched 
primers as previously described (Levi et al., 1991). After restriction enzyme digestion using 
MvaI (Toyobo Company, Tokyo, Japan), PCR was performed in a 20µl reaction mixture 
using Ampli-Taq Gold DNA polymerase (Perkin Elmer Applied Biosystems Division, Foster 
City, CA) according to the manufacturer's manual. In a second PCR and after another round 
of MvaI digestion, wild type fragments were cleaved to yield 29 and 106 base pair (bp) 
products, whereas mutant fragments yielded 135 bp. Electrophoresis of the digested sample 
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on 3% agarose gel confirmed the mutation band. SW480, a colon cancer cell line, and HT29 
were used as a positive and negative control for K-ras codon 12, respectively (Fig. 2). 
2.2.2 Sequencing analysis  
The mutant fragments identified by enriched PCR-RFLP were confirmed by direct sequencing. 
The sequence of codon 12 was determined by automated fluorescent DNA sequencing using 
the dideoxy chain termination method (Sanger et al., 1997). PCR products were used for the 
cycle sequencing. The products were purified using Centricon-100 (Amicon Inc, Beverly, MA) 
following the manufacturer’s protocol and then were sequenced using the Dye Terminator 
Cycle Sequencing Ready Reaction (Perkin Elmer Applied Biosystems Division, Foster City, 
CA) according to the manufacturer’s instructions as reported previously (Watari et al., 2002). 
The sequencing reaction products were analyzed on ABI PRISM GeluxeTM (Perkin Elmer) on 
an ABI PRISM 310 DNA sequencer (Perkin Elmer). 
 
 
Fig. 2. A K-ras mutation in codon 12 was detected by enriched PCR-restriction fragment 
length polymorphism in gastric intestinal metaplasia (GIM) from patients with and without 
gastric cancer. The arrows indicate the positions of the mutant (135bp) and wild-type 
(106bp) bands. Lane 1: GIM from patient with gastric cancer; lanes 2-4: GIM from patients 
without gastric cancer; lane 5: SW480 as positive control; lane 6: HT29 as negative control. 
2.2.3 Detection of proliferation and apoptosis 
Dewaxed paraffin sections were examined by the avidin-biotin peroxidase complex (ABC, 
Vector Laboratories, Burlingame, CA) method using the primary antibody for Ki-67 antigen 
of proliferating cells (mouse IgG, Invitrogen, Calsbad, CA, USA). The slides were treated 
with the antigen-retrieval technique based on microwave oven heating. 
Apoptotic cells in situ were detected by the terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end labeling (TUNEL) method as previously described (Gavrieli et al., 1992). The 
slides were dewaxed and rehydrated through a graded alcohol series. The tissue specimens 
were digested with 20 µg/ml proteinase K (Boehringer, Mannheim, Germany) for 30 min at 
37˚C. After treating with a 2% H2O2 solution, the sections were preincubated with 100 mM 
potassium cacodylate, 2 mM cobalt chloride, 0.2 mM dithiothreitol, pH 7.2 for 3 min, and 
then were incubated with the same buffer containing 0.3U/µl terminal deoxynucleotidyl 
transferase (TdT, GIBCO BRL Gaithersburg, MD) and 0.04 nmol/µl biotinylated dUTP 
(Boehringer, Mannheim, Germany) in a humid chamber at 37˚C for 1 hr. The slides were 
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rinsed in 30mM sodium citrate, 300 mM sodium chloride for 30 minutes at RT, and washed 
in phosphate-buffered saline (PBS). After blocking with 10% rabbit serum for 10 min and 
rinsing briefly in PBS, sections were incubated with ABC for 30 min at RT. Labeled cells 
were visualized with diaminobenzidine. The sections were then counterstained with 
hematoxylin. In GIM in each case, a minimum of 300 cells from some fields randomly 
selected were counted and the fractions (%) of cells that showed positive nuclear staining for 
Ki-67 antigen (Fig. 3A) and TUNEL (Fig. 3B) were considered to be the proliferative indices 
(PI) and the apoptotic indices (AI), respectively. The PI and AI were determined 
independently by a single physician (J.W.).  
 
 
Fig. 3. Ki-67 staining and TUNEL in a representative case of gastric intestinal metaplasia 
(GIM). (A) Proliferating cells were found predominantly in the lower portion of GIM. (B) 
Apoptotic cells (arrows), detected by the TUNEL method were seen. 
2.3 Consent and ethical approval 
Regarding the above studied, written informed consent was obtained from the patients, and 
the Ethics Committee of Asahikawa Medical University gave their approval for this study. 
2.4 Statistical analysis  
All data are presented as means ± SEM. Statistical analyses were assessed by the Student t 
test, by Mann-Whitney U test, by the Kruskal-Wallis test, by chi-square test and by Fisher’s 
exact test. The Wilcoxon signed-rank test was used in the comparison of parameters before 
and after treatment in the same patient. Statistical significance was defined as p<0.05. 
3. Results 
3.1 Study 1 
3.1.1 Histologic score at initial diagnosis 
Patients in Group CG had evidence of chronic gastritis, but did not have GIM. At the initial 
diagnosis, GIM scores in Group DYS were significantly higher than those in Group IM 
(p<0.05) and Group CG (p<0.0001) (Fig. 4).  
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Fig. 4. Initial histologic GIM scores and changes in the score in patients followed up over 4 
years after H. pylori eradication. GIM scores were significantly higher in Group DYS than in 
Group IM before eradication (p<0.05). At initial stage, none of the patients in Group CG had 
GIM, although all had gastritis. GIM scores in Groups IM and DYS were higher than those 
in Group CG at 1 year after treatment (p<0.05 and p<0.0005, respectively), as well as at 2 to 4 
years. After eradication of H. pylori in both Groups IM and DYS there were slow minor 
declines of GIM scores that were not statistically significant. However, GIM score in patients 
from Group CG increased even if H. pylori was eliminated, and this difference was 
statistically significant (p=0.001, Kruskal-Wallis test). The GIM score in Group CG was 
significantly lower than in Groups IM and DYS at the 1-year follow-up evaluation, as well as 
at the end of 4 years. 
3.1.2 Reactivity against mAb Das-1, TC22-4 and anti-p53 before treatment 
In Group CG, with chronic gastritis without GIM, there was no immunoreactivity with any 
of the gastric mucosal samples against mAb Das-1, TC22-4 and anti-p53 (Fig. 5). In Group 
IM patients, the immunoreactivity against mAb Das-1 was 39% (13 of 33) and against TC22-
4 it was 36% (12 of 33). The reactivity against anti-p53 was 3% (1 of 33). The reactivity of 
mAb Das-1 is diffuse cytoplasmic with higher intensity at the periphery of cells and is 
present in both goblet cells and non-goblet cells in the GIM areas (Fig. 6E). The TC22 
reactivity is seen as intracellular cytoplasmic dot-like staining in a punctate manner (Fig. 
6F), and p53 staining is detected in scattered cells mainly in the nuclei of the glands (Fig. 
6N). In patients from Group DYS, the reactivity of mAb Das-1, TC22-4 and anti-53 in GIM 
areas away from dysplastic areas was 63% (17 of 27), 48% (13 of 27) and 15% (4 of 27), 
respectively. Twenty-four of 27 (89%) of patients showed positive reactivity with mAb Das-1 
at the dysplastic areas (Fig. 5). If the dysplastic area is positive with mAb Das-1, GIM areas 
away from the dysplastic areas of the same patients were also positive. Of the 13 patients 
who were positive with TC22-4 in the GIM areas, 11 of these 13 (85%) patients’ dysplastic 
areas also showed reactivity to TC22-4. The mAb Das-1 reactivity showed progressive 
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increase between Group IM and Group DYS (Fig. 5). TC22 expression, although numerically 
higher in Group DYS than in Group IM (48% vs. 36%), was not statistically significant. 
However, in the same patients following eradication, as described below, there was a 
significant decline of immunoreactivity. p53 expression in the GIM areas in the 2 groups (IM 
and DYS) were 3% vs. 15% respectively. Anti-p53 reactivity was much higher in the 




Fig. 5. Reactivity of GIM to mAb Das-1, TC22-4 and anti-p53 in patients from Groups CG, 
IM, and DYS before treatment. In Group CG, no reactivity to mAb Das-1, TC22-4 and anti-
p53 was found in the normal mucosa or in gastritis area without GIM. The 
immunoreactivity of mAb Das-1 to GIM from Group C was higher (63%) than Group IM 
(39%) (p=0.069). In the GIM areas from Group DYS, mAb TC22-4 reactivity (48%) was 
higher than that from Group IM (36%). However, in the dysplastic areas of Group DYS, the 
mAb Das-1 reactivity was the highest (89%). Each of the dysplastic areas and GIM mucosa 
away from this mucosal cancer area from the same patients reacted with mAb Das-1. Anti-
p53 reactivity was absent in normal and inflamed mucosa as well as in GIM areas from 
Groups CG and IM (3%), except in Group DYS where 4 of 27 (15%) showed reactivity at the 
GIM areas. However, 59% of dysplastic areas reacted with anti-p53. 
3.1.3 Changes of the GIM score after eradication of H. pylori during prospective 
follow-ups 
GIM scores before and after treatment of H. pylori in each group are shown in Fig. 4. 
Although initially none of the patients in Group CG had GIM, during the follow-up period, 
8 patients at 1 year and 6 additional patients developed GIM during subsequent 4 years 
(p=0.001, Kruskal-Wallis test). Furthermore, GIM scores were higher in Group IM and DYS 
than in Group CG at 1 year after treatment (p<0.05 and p<0.0005, respectively). At 2-4 years 
after treatment, GIM scores continued to increase in Group CG and there was a significant 
difference in GIM score between Group CG and Group IM (p<0.05) as well as Group DYS 
(p<0.01) at 4 years. This difference suggests chronicity of the metaplastic process over a long 
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time. Although in Group DYS there was some decline of GIM score over 4 years, it was not 
significant. The histologic scores in Group IM remained essentially unchanged (Fig. 4).   
3.1.4 Changes in the GIM phenotypes on the basis of mucin histochemistry before 
and after treatment for H. pylori 
Patients from Group CG did not have GIM before treatment, however, 14 patients (39%) 
developed GIM during the 4 years of follow-up and GIM in these patients consisted of type 
I (complete type) in 8 (57%) and type II or III (incomplete type) in 6 (43%) patients (Table 2). 
In Group IM, type I and type II/III were found in 22 (67%) and in 11 (33%) patients 
respectively before treatment for eradication of H. pylori. On the contrary, in Group DYS, the 
majority (59%) (16 out of 27) of GIM belonged to type II/III (incomplete type) compared to 
type I (41%, 11 of 27), prior to treatment. The incidence of incomplete type of GIM was 
significantly (p<0.05) higher in Group DYS than in Group IM. In Group IM, of the 22 
patients initially classified as type I GIM, 7 (32%) had “progressed” to type II/III, while in 
two no GIM was found after treatment and three of the 11 patients initially classified with 
type II/III had “regressed” to type I GIM. Similarly, in Group DYS, 5 of the 11 patients 
(46%) with type I GIM changed to type II/III, and in one, no GIM was found following 
treatment. Three of 16 patients (19%) initially classified as type II/III GIM regressed to type I 
and one had no GIM after eradication (Table 2).  
3.1.5 Reactivity to mAb Das-1, TC22-4 and anti-p53 in GIM during the follow-up period  
mAb Das-1 did not react with any of the 36 samples in Group CG who had chronic gastritis 
without GIM prior to treatment (Fig. 5). Of the 39% of patients in Group CG who developed 
GIM during the 4 year follow-up period subsequent to the eradication of H. pylori, 43% (6 of 
14) showed reactivity to mAb Das-1, similar to the incomplete (type II/III) determined by 
immunohistochemistry. Fig. 6A and 6B are an example from a patient in Group CG showing 
chronic gastritis in pretreatment biopsy (Fig. 6A) and subsequent development of GIM (Fig. 
6B) despite eradication following triple therapy. However, no mAb Das-1 reactivity to GIM 
was found in this patient (Fig. 6C). The H&E staining, and mAb Das-1 reactivities of serial 
sections of the biopsy specimen from a patient in Group IM are shown in Fig. 6D and E, 
respectively. Fig. 6G and H show serial sections from the biopsy specimen from a patient in 
Group DYS (GIM area) stained by H&E and mAb Das-1 respectively. The mAb Das-1 
reactivity is restricted to the glandular epithelium in the GIM areas (Fig. 6E and 6H). Both 
the non-goblet metaplastic cells and goblet cells reacted with mAb Das-1, and normal gastric 
mucosa did not react. Fig. 6J and 6K show serial sections from a patient in Group DYS with 
cancer stained by H&E and mAb Das-1 respectively. Cancer cells invading microscopically 
into the sub-mucosa can be seen. The reactivity with mAb Das-1 against the dysplastic 
glands is more diffuse and intense (Fig. 6K).     
There were 30 patients (13 in Group IM and 17 in Group DYS) that reacted to mAb Das-1 
before treatment. When the immunoreactivity in the biopsy tissue from the same patients 
were compared before and after treatment, in 40% of the patients the reactivity disappeared 
(p<0.0001) after eradication of H. pylori (Table 3, Fig. 6I), despite the presence of GIM. The 
disappearance of the reactivity was seen in both Group IM and Group DYS.  
The reactivity of mAb TC22-4 is restricted to GIM areas both in goblet and non-goblet cells. 
The reactivity is dense globular dot like staining mainly along the apical areas (Fig. 6F).  In 
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  Pretreatment Posteradiucation 
  Types Number Types Number 
Group CG (n=36) No GIM  I 8 
II/III 6 




  II/III 7 
Total   20 a 
  
II/III c 11 
I 3 
  II/III 8 
Total   11 
Group 
DYS 
(n=27) I 11  I 5 
   II/III 5 




  II/III 12 
Total   15 b 
a GIM disappeared in 2 patients after eradication. 
b GIM disappeared in 2 patients after eradication. 
c P<0.05 in the incidence of type II/III GIM between Group IM and Group DYS in pretreatment. 
Table 2. Types of GIM on the basis of mucin histochemistry  
 
 Pretreatment Posteradiucation  
 Positive Positive Negative P 
Groups IM + DYS 30 (100%) 17 (57%) 12 (40%) <0.0001 
Group IM 13 (100%) 7 (54%) 5 (38%) <0.01 
Group DYS 17 (100%) 10 (59%) 7 (41%) <0.007 
Table 3. Changes in the immunoreactivity of mAb Das-1-positive GIM after H. pylori 
eradication in the same patients 
Figure 6F. Twelve of 33 patients (36%) in Group IM were positive prior to treatment, and 
following treatment the reactivity declined to 6 of 29 (21%) (Fig. 6M). There was no 
difference in TC22 reactivity before and after treatment. Seven patients in Group IM and 10 
patients in Group DYS were positive for both mAb Das-1 and TC22-4 reactivity. Following 
eradication of H. pylori, the immunoreactivity for both the markers disappeared in 5 of the 7 
patients in Group IM (p<0.05).  However, in only 3 of 10 patients in Group DYS was the 
reactivity absent. This was not significant (Table 4).  
 
 Pretreatment Posteradiucation  
 Positive Positive Negative P 
Groups IM + DYS 17 (100%) 9 (53%) 8 (40%) <0.005 
Group IM 7 (100%) 2 (29%) 5 (38%) <0.05 
Group DYS 10 (100%) 7 (70%) 3 (41%) NS 
Table 4. Changes in the immunoreactivity of TC22-4-positive GIM after H. pylori eradication 
in the same patients 
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Fig. 6. Representative sections of H&E and immunoperoxidase staining with mAb Das-1, 
TC22-4, and anti-p53. (A and B) Example of a patient from group CG whose gastric mucosa 
only had mild gastritis, (A) without any GIM before treatment (magnification, 200X), but (B) 
GIM clearly developed after eradication (magnification, 200X). (C) However, GIM did not 
react with mAb Das-1 after treatment (magnification, 200X). In a patient from group IM, 
serial sections from the initial biopsy specimen before eradication show (D) GIM (H&E 
magnification, 200X) that reacted with both (E) mAb Das-1 (magnification, 200X) and (F) 
TC22-4 (magnification, 400X). Serial sections of the biopsy tissue from a patient from group 
DYS before treatment show (G) GIM (H&E magnification, 200X) and (H) reactivity to mAb 
Das-1 (magnification, 200X). A serial section of the same tissue also reacted with TC22-4 
(figure not shown). (I) The reactivity to mAb Das-1 (magnification, 200X) disappeared in 
two fifths of the patients from both groups IM and DYS (Table 3) after H. pylori treatment 
(p<0.0001). (J and K) Representative pictures of the serial tissue sections from a patient in the 
severe dysplasia group (group DYS) stained with (J) H&E and (K) mAb Das-1. (J) Cancerous 
glands, with microinvasion into the submucosa, seen in H&E staining (magnification, 100X), 
and all of these tissue strongly reacted with (K) mAb Das-1 (magnification, 100X). (L) GIM 
in a patient from group IM after eradication of H. pylori. (M) TC22 reactivity disappeared in 
this patient (H&E magnification, 200X). (N) GIM from a patient from group DYS stained 
with anti-p53. p53 protein staining is shown in scattered cells (arrows), mainly in the nuclei 
of the glands. 
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The p53-positive nuclear staining was mainly detected in the dispersed cells mostly at the 
GIM glands located at the deeper plane (Fig. 6N, arrows). In Group IM, p53 expression was 
observed in only one of 33 patients before treatment, and its expression was noted in one 
additional patient during the follow-up period after treatment. In Group DYS, in the GIM 
areas, 4 of 27 (15%) had p53 expression at initial examination. During the follow-up period, 
additional patients, 7 of 25 (28%), exhibited p53 expression. However, in the dysplastic areas 
in Group DYS, p53 expression was high (16 of 27, 59%). The p53 expression did not change 
in these patients during the follow-up period. All of the patients in Group DYS who were 
anti-p53 positive, also had mAb Das-1 reactivity and TC22 expression (both GIM and 
dysplastic areas). 
3.2 Study 2 
3.2.1 K-ras codon 12 mutations in GIM  
The mutant K-ras in codon 12 was detected in 18 (46.2%) of 39 GIM in Group IM and 1 
(1.9%) of 53 GIM areas away from cancer in Group DYS before eradication, and 2 (3.8%) of 
53 cancers, respectively. One case who had a K-ras mutation in Group DYS belonged to 
Group DYS-1. One of the 2 cancers which were positive for K-ras mutations was also 
positive in parallel with the GIM areas. Group IM showed a significantly more frequent 
incidence of K-ras codon 12 point mutations than Group DYS (p<0.005). Moreover, the 
incidence (46.2%) of the K-ras gene alterations significantly decreased to 12.8% (5 of 39) after 
treatment in Group IM but not in Group DYS. Of the lesions with K-ras mutations in Group 
IM before treatment, GGT (Gly) showed AGT (Ser) transition in 9 (50.0%), GAT (Asp) 
transition in 6 (33.3%) and TGT (Cys) transversion in 3 (16.7%). Following treatment, four 
(75.0%) showed a transition to AGT (Ser) and 1 (25.0%) showed a transition to GAT (Asp). 
Hence, mutation patterns showed convergence to Ser transformation by H. pylori treatment. 
The mutation pattern in the patient from Group DYS-1 was AGT (Ser). After eradication, the 
patterns of AGT (Ser) disappeared and one subject who had previously been negative for K-
ras mutation showed a positive finding for the K-ras mutation of GAT (Asp). The cancer 
showed two patterns: GCT (Ala) in 1 and GTT (Val) in 1 (Table 5). 
 
 Helicobacter pylori eradication 
  Before n  After n 
Group IM AGT (Ser) 9  AGT (Ser) 4 
 GAT (Asp) 6  GAT (Asp) 1 
 TGT (Cys) 3    
Group DYS-1 AGT (Ser) 1  GAT (Asp) 1 
Cancer areas GCT (Ala) 1    
  GTT (Val) 1    
Table 5. Patterns of K-ras mutation in gastric intestinal metaplasia 
3.2.2 Cell kinetics of GIM 
PI and AI in IM before H. pylori eradication were 36.71% and 0.27% in Group IM, 45.69% 
and 0.52% in Group DYS, respectively. PI in Group DYS was significantly higher than that 
in Group IM (p<0.05). AI also showed a similar tendency, but the difference did not reach 
statistical significance. Regarding the cell kinetics after treatment in each group, PI and AI 
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were 40.43% and 0.47% in Group IM, 42.32% and 0.83% in Group DYS, respectively. 
Although there were no significant changes in the PI before and after H. pylori eradication, 
the level of AI increased after H. pylori eradication in both groups (p<0.05 in Group IM) 
(Table 6). 
 
 PI AI AI/PI ratio 
 H. pylori eradication H. pylori eradication H. pylori eradication 
  Before After Before After Before After 










* p<0.05, Numbers are mean ± standard error. PI, proliferative indices; AI, apoptotic indices; H. pylori, 
Helicobacter pylori 
Table 6. Comparison of cell kinetics before and after Helicobacter pylori eradication 
 
 Neutrophils Mononucler cells Intestinal metaplasia 
 H pylori eradication H pylori eradication H pylori eradication 
 Before After Before After Before After 
Group IM 0.65 ± 0.10 a 0.03 ± 0.03 a 1.54 ± 0.11 c,d 1.03 ± 0.10 c 1.4 ± 0.6 f 1.3 ± 0.8 
Group DYS 0.40 ± 0.13 0.20 ± 0.09 1.15 ± 0.17 d 1.00 ± 0.10 2.1 ± 0.9 f 1.9 ± 0.9 
a,c,d p<0.0001, c p<0.005, d p<0.05, e p<0.005, f p<0.05, Numbers are mean ± standard error. H. pylori, 
Helicobacter pylori 
Table 7. Comparison of scores for histological findings before and after Helicobacter pylori 
eradication 
3.2.3 Inflammation and GIM scores 
The grade of inflammation and GIM before and after treatment was shown in Table 7. All 
GIMs investigated in the current study were diagnosed as incomplete type without 
dysplastic glands. At 1 year after successful H. pylori eradication, the median score of 
inflammation such as neutrophils and mononuclear cells significantly improved in Group A 
(p<0.0001 and p<0.005, respectively), but it did not change in Group B. The score of 
mononuclear cells was significantly higher in Group IM than in Group DYS (p<0.05), 
although no significant difference was observed in the neutrophils between the two groups. 
The GIM scores were also significantly higher in Group DYS than in Group IM before H. 
pylori therapy (p<0.05). After 1 yr of follow-up, however, the GIM score remained 
unchanged in comparison to their pretreatment values in both Groups IM and DYS.   
4. Discussion 
4.1 Study 1 
In this study, we show that H. pylori eradication did not significantly improve GIM 
histologically, but changed the cellular phenotype, as evidenced by the significant reduction 
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of reactivity against monoclonal antibody, mAb Das-1, indicating a reduction of colonic 
phenotype (incomplete type) of metaplasia over the course of subsequent follow-up, up to 4 
years. This was further supported by prospectively following the same patients who were 
initially positive. We further demonstrate that eradication of H. pylori might reverse TC22 
expression at the earlier stage (Group IM). However, once dysplasia/cancer has developed 
in the background mucosa (Group DYS), both cellular phenotype, as detected by mAb Das-1 
and neoplastic marker TC22, did not show significant change following H. pylori 
eradication. These data support the conclusion reported by some investigators that at a 
certain stage of progression of GIM there is a “Point of no return” (Wong et al., 2004; 
Wright, 1998). 
GIM is considered to be a pre-cancerous lesion of the stomach (Uemura et al., 2001; Correa 
& Shiao, 1994; Wong et al., 2004), especially when it is incomplete or colonic type (type II & 
type III) metaplasia (Filipe & Jass, 1986; Mirza et al., 2003). There are an equal number of 
studies showing either improvement or no change in the incidence of gastric cancer 
following eradication of H. pylori (Table 1). However, a large population based study 
showed decrease in cancer incidence following eradication of H. pylori (You et al., 2006; Take 
et al., 2005; Wong et al., 2004). The reasons for these discrepancies are the limited number of 
patients in some of the series, short follow-up, and also unawareness of the stage when the 
treatment was initiated. Our results support the reports that showed that 2 years following 
H. pylori eradication there was no significant histologic improvement in GIM (Forbes et al. 
1996; Tucci et al., 1998; Tepes et al., 1999; Kim et al., 2000; Kuipers et al., 2004), although two 
other reports showed improvement (Kokkola et al., 2002; Correa et al., 2000). It was 
suggested that effective anti-H. pylori treatment might interfere with the pre-cancerous 
process, mostly by increasing the rate of regression of GIM (Correa et al., 2000). Our study 
demonstrates that this “regression” may be related to the change of cellular phenotype. 
Taking into account previous studies and our finding, it, therefore, appears that eradication 
of the bacteria may not influence the course of the histologic process (Farinati et al., 1998). 
We further demonstrate that even after eradication of H. pylori, in 14 of 36 patients (39%) 
who at initial diagnosis had gastritis without GIM (Group CG), developed GIM 
subsequently during the 4 years of follow-up evaluation. However, it appears that these 
GIMs are mostly of complete type (type I) of metaplasia that have a low risk for gastric 
carcinoma (Filipe et al. 1986; Mirza et al., 2003; Wong et al., 2004). Wong et al suggested that 
eradication of H. pylori should be done prior to the development of GIM in order to prevent 
gastric cancer (Wong et al., 2004). Our data further support that once the dysplastic process 
has occurred, eradication of H. pylori may not be helpful in changing the course (Sakaki et 
al., 2002; Asaka et al., 2002). Some investigators showed that older subjects are more likely to 
demonstrate progression in GIM in persistent H. pylori infection than younger patients 
(Sung et al., 2000; Sakaki et al., 2002; Asaka et al., 2002). Indeed, the average age of the 
patients in Group DYS was significantly higher than from Group CG and IM (p<0.005 and 
p<0.05, respectively), indicating that GIM in Group DYS was in an advanced stage among 
the three groups. The mean age of the patients in Group IM was in between the mean ages 
of Group CG and Group DYS. Furthermore, the GIM score in Group DYS is significantly 
higher than Group IM (p<0.05). Hence, our findings support the postulation that GIM grade 
ensues sequentially over a period of a decade (Uemura et al., 2001; Correa et al., 1990).  
We previously reported a highly significant (p<0.0001) reactivity of mAb Das-1 against GIM 
adjacent to gastric cancer when compared to GIM from non-cancer patients (Mirza et al., 
2003). We further reported that the reactivity of mAb Das-1 in other precancerous 
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conditions, such as Barrett’s epithelium was highly sensitive and specific (100%) (Das et al., 
1994). In the small intestine, although mAb Das-1 does not react with normal epithelium, 
mAb Das-1 reactivity was evident in most of the small intestinal adenoma and 
adenocarcinoma (Onuma et al., 2001). All of these studies suggest a colonic or incomplete 
phenotype of metaplasia in the pre-cancerous conditions of the esophagus, stomach and 
small intestine. The present study shows that the immunoreactivity to mAb Das-1 was 
higher in the GIM in patients from Group DYS compared to those from Group IM (p<0.05) 
at the initial diagnosis before H. pylori eradication. Furthermore, mAb Das-1 reacted with 
GIM areas away from the dysplastic areas from each of the patients whose dysplastic areas 
were positive with mAb Das-1. Twelve out of 30 patients (40%) with GIM from Groups IM 
and DYS who were positive to mAb Das-1 before treatment, lost the reactivity (p<0.0001) 
after eradication of H. pylori, suggesting the reversibility of the process if H. pylori is 
eradicated. Thus, the patients with H. pylori infection with GIM that showed the reactivity 
for mAb Das-1 (incomplete type of metaplasia) may benefit from eradication for future 
development of cancer. This observation may be clinically useful for surveillance. 
TC22 is a neoplastic marker. It is expressed by transformed cells but not by normal epithelial 
cells (Lin et al., 2002). In the present study, TC22-4 reactivity in GIM did not significantly 
change after eradication in both Group IM and DYS. Thus, the reactivity of Das-1 against 
GIM may suggest an early stage of neoplastic process compared with that of TC22-4. In a 
pilot study, we also observed that the frequency of mAb TC22-4 reactivity in gastric cancer 
was 86% (19/22) (Das-Bhattacharya et al., 2001). In each of these 19 patients, the GIM area 
away from the cancer area was also positive for TC22. Therefore, eradication of H. pylori at 
this stage may not be beneficial to avoid cancer development.  
Mutation of the tumor suppressor gene p53 has been described in gastric carcinogenesis. 
Some GIM shows p53 mutations and its overexpression (El-Zimaity et al., 2001; Shiao et al., 
1994; Imatani et al., 1996 ; Hamamoto et al., 1997; Jones et al., 1997), and accumulation of p53 
is detected in gastric mucosa infected with H. pylori (Hibi et al., 1997; Satoh  et al., 2001). Of 
interest, it was reported that p53 overexpression decreased after eradication of H. pylori 
(Hibi et al., 1997; Jones et al., 1997). Some of the discrepancies may be due to various 
reagents, and in some reports, p53 positivity index was used by calculating p53-positive 
cells in gastric glands (Hibi et al., 1997; Jones et al., 1997). p53 expression in our patients 
with GIM was very low, 3% in Group IM, and only 15% in Group DYS, and there was no 
regression following treatment. In the patients from Group DYS before treatment, the 
incidence (15%) of p53 expression was significantly lower than that of mAb TC22-4 
reactivity in GIM areas (48%). In the paired samples of tissue with dysplasia/cancer, the 
overexpression of p53 increased from 15% in the GIM areas to 59% in the dysplastic areas. 
However, TC22 expression was essentially the same. Thus, p53 protein accumulation seems 
to be a late event, whereas TC22-4 expression is an earlier event, as also reported in colonic 
neoplasm (Lin et al., 2002).  
As many investigators pointed out, it will certainly need a much longer follow-up period, 
more than 4 yrs., in order to evaluate the effect of eradication for the cancer prevention. 
However, the end-point of the current study was to assess the changes in the expression of 
biomarkers in GIM, one associated with cell phenotype and the other associated with 
epithelial neoplasia, but not the development of gastric cancer after H. pylori treatment. 
Indeed, we recently found that cell kinetics and genetic alterations, i.e. microsatellite 
instability and K-ras mutations in GIM, play a role in the early events leading to gastric 
carcinogenesis, and H. pylori eradication settled these genetic events during only the one-
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year post-treatment period (Tanaka et al. 2006; Watari et al. 2008). Thus, we believe that the 
follow-up period, up to 4 yrs in this study, is enough to investigate the changes in cellular 
phenotype and neoplastic biomarkers related to carcinogenesis after H. pylori eradication. 
Taking our present and previous data (Tanaka et al. 2006; Watari et al. 2008) together, 
eradication of H. pylori may inhibit this intracellular dysfunction; thereby may inhibit 
carcinogenesis.   
The data presented in the current study based on careful initial stratification of patients by 
an independent expert pathologist without the knowledge of clinical information, and 
prospective follow-up for 4 years, provide important information about the cellular changes 
in the GIM using the two novel biomarkers. Strategies to identify individuals who are at a 
“high risk” for gastric cancer screening are very much needed. Immunostaining with mAb 
Das-1 and TC22-4, that can easily be performed along with routine histology, may be 
clinically useful in this regard. 
4.2 Study 2 
The mutant K-ras was detected in only 3.8% of the cancer, and this finding was consistent 
with the findings of previous reports (Tahara et al. 1993; Arber et al., 2000; Hiyama et al., 
2002). On the other hand, we found a significantly higher frequency of K-ras mutations in 
GIM (46.2%) in patients with chronic gastritis in comparison those with gastric cancer (1.9%) 
with H. pylori infection. Furthermore, we also observed that K-ras mutations significantly 
decreased to 12.8% after H. pylori eradication. Regarding the K-ras mutation types in Group 
IM, various patterns such as G to A (Ser and Asp) transitions and G to T (Cys) transversion 
were seen before treatment. It is interesting to note that after H. pylori eradication, most 
individuals (80.0%, 4 of 5) showed transition to AGT (Ser) while other mutation patterns 
such as TGT (Cys) and GAT (Asp) disappeared. In our data, since the number of cases that 
could be investigated based on the changes in the K-ras mutation patterns was small, 
statistical significance could therefore not be applied to them. These results indicate, 
however, that K-ras mutations in GIM with GAT and TGT types may thus be early and 
unstable in gastric carcinogenesis because they disappeared after H. pylori treatment. AGT 
(Ser) still remained in most cases treated with H. pylori in our study. Gong et al. reported the 
G to A transition (Ser) to be important for the progression of gastric mucosal cells to a more 
advanced premalignant stage (Gong et al., 1999). Lee et al. also showed a similar result, so 
that frequent G to A transversions were detected in gastric cancers (Lee et al., 1995). Taking 
both our results and other data into consideration, mutations with AGT (Ser) were thus 
considered to more likely be advantageous in K-ras gene alterations. Hiyama et al. reported 
interesting data in which K-ras mutations were detected in 3.0% in the background mucosa 
without cancer and in 10.9% in those with cancer, thus indicating a significant difference. In 
addition, most (70%) of the patterns of K-ras mutations detected in chronic gastritis patients 
were G to C transitions (GCT, Ala) (Hiyama et al., 2002). However, their data do not show 
K-ras gene alterations in only GIM, and thus their findings are different from those of our 
investigation. In the current study, we used a laser capture microdissection system to extract 
DNA from GIM. This method allows the procurement of relatively pure metaplastic cell 
populations from the complex heterogeneous cell mixtures (Bonner et al., 1997). Therefore, it 
is considered that the specificity of genetic alterations in DNA extracted selectively from 
GIM (Dillon et al., 2001). Our results may suggest that the mutations with AGT (Ser) is 
important in gastric tumorigenesis, but not in others. We investigated here on K-ras 
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oncogene alterations in GIM using only one biopsy sample obtained from the antrum. It will 
be necessary to study whether the patients with mutations have the same mutation in 
multiple GIM foci in each patient in order to confirm more clearly the role of K-ras mutation 
in GIM.   
H. pylori eradication dramatically improved the inflammation scores, i.e. neutrophils and 
mononuclear cells, but not the degree of GIM, thus confirming the findings of previous 
studies in which the effect of H. pylori eradication therapy led to an improvement in the 
severity of inflammation (Witteman et al., 1995; van der Hulst et al., 1997). However, no 
significant improvement in the inflammation scores was found in patients with gastric 
cancer (Group DYS). Although the reason cannot be clearly explained, one possibility for 
this finding may be the small number patients investigated in comparison to those of Group 
IM. Interestingly, the score of mononuclear cells in Group IM showed a significantly higher 
level than that in Group DYS at the pretreatment assessment although no significant 
differences in the neutrophil scores were observed between Groups IM and DYS. Recently, 
Brembeck et al have reported a fascinating data that they generated a novel mouse model in 
which the cytokeratin 19 promotor, specifically active in pancreatic ductal cells, is fused to 
mutant K-ras (Brembeck et al., 2003). These results showed dramatic evidence of 
lymphocytic infiltration around the periductal area, in both the interlobular and intralobular 
pancreas of transgenic mice, which may thus act as an adaptive immune response to 
activated ras-mediated signaling. Taking both our findings and previous results into 
consideration, a frequent K-ras mutation in GIM may therefore be associated with evidence 
of lymphocyte infiltration but not with gastric carcinogenesis, even though the K-ras gene is 
considered to be an oncogene.   
In the present study, we first found the cellular proliferation of GIM to significantly be up-
regulated in patients with gastric cancer more than in those without gastric cancer. As for 
apoptosis, there was a similar tendency even though no significant difference was seen. This 
finding supports the report of Shiotani et al that GIM results in proliferation-dominant cell 
kinetics may be one of the components of gastric carcinogenesis (Shiotani et al., 2005). 
Commonly, an imbalance of cell proliferation and apoptosis is known to play a role in 
cancer development, and tumor progression should be thus be considered in the context of 
both proliferative activity and cell loss (Wyllie, 1996). One of the pathways by which H. 
pylori is linked to gastric carcinogenesis may be related to the disruption of the cell kinetics. 
Uemura et al. reported that H. pylori eradication inhibited the development of new cancers 
in patients who underwent EMR for 2 years after EMR, while 9% of the patients who were 
not treated with this treatment developed new early stage gastric cancers after 3 years of 
follow-up (Uemura et al., 1997). From the standpoint of this clinical report by Uemura et al 
and our results, the increase of apoptosis in GIM by the clearance of H. pylori may be 
associated with the prevention of cancer development. To our knowledge, there has only 
been one study that has assessed the cell kinetics in H. pylori-associated GIM in patients with 
gastritis both before and after H. pylori eradication, although the sample size investigated in 
that study was small (14 cases) (Leung et al., 2001). They demonstrated a remarkable 
reduction in proliferation whereas the degree of apoptosis remained unaltered in GIM by 
treatment, by which the clearance of H. pylori may retard gastric carcinogenesis. However, 
we failed to detect such an association in the current study. This discrepancy seems to be 
derived from a few factors: namely, the difference in the sample number and the sampling 
error. As mentioned in the results, the severity of GIM was significantly higher in patients 
with cancer (Group DYS-1) than in those with chronic gastritis (Group IM) prior to 
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treatment. Hence, an evaluation of the cell kinetics in GIM from the Group IM cases was 
therefore particularly difficult.  
We recently found microsatellite instability (MSI) as a genetic alteration in H. pylori-related 
GIM to play a role in the early events leading to gastric carcinogenesis. H. pylori eradication 
reduced MSI during the one-year post-treatment period (Tanaka et al., 2006). In this 
prospective study, however, our current results suggest that K-ras codon 12 mutations in 
GIM may not be associated with gastric carcinogenesis. There are early events in K-ras 
mutations, which are influenced by inflammation-related H. pylori infection, and some 
mutations such as AGT (Ser) may thus be selected by eradication. Furthermore, these 
unstable K-ras mutations in GIM may be related to the lymphocyte infiltration caused by H. 
pylori infection. If H. pylori is eradicated before the development of stable mutations, then 
the risk of gastric cancer will likely be prevented. Furthermore, apoptosis in GIM showed 
the increase based on the treatment. Our 1-year prospective study may explain that the 
prevention of gastric cancer by H. pylori therapy is not associated with an improvement of 
K-ras mutations and the degree of GIM, but up-regulation in apoptosis control in GIM 
contributes to retard gastric carcinogenesis.  
5. Conclusions 
H. pylori eradication does not reduce the histologic GIM score, but changes the cellular 
phenotype of GIM. This change of phenotype may be an important factor in the reduction of 
cancer incidence after eradication of H. pylori. Furthermore, K-ras mutations in GIM do not 
always play a role in gastric carcinogenesis but cell kinetics, especially apoptosis, in GIM 
may contribute it. 
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